Abstract
Resveratrol, a polyphenolic phytoalexin, is one of the most extensively studied natural products, with wide ranging biological activity and tremendous clinical potential. First identified from fruits and plants, in particular grapes and wines, its positive effects on a variety of disease states have been unraveled over the past decade or so. Most noticeable are its anti-thrombogenic, anti-inflammatory, cardio-protective, neuro-protective, anti-aging, and cancer preventive and therapeutic activities. Recent data also indicate that depending upon the concentration/dose, resveratrol can trigger or block cell death signaling in tumor cells. Considering the heightened interest in this compound, here we present a short review on the biological activity of this remarkable compound, with a specific focus on its effects on cell survival and death signals.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y (2004) Anticancer Res 24:2783–840
Aggarwal BB, Shishodia S (2006) Biochem Pharmacol 71:1397–1421
Ahmad KA, Clement MV, Hanif IM, Pervaiz S (2004) Cancer Res 64:1452–1459
Ahmad KA, Clement MV, Pervaiz S (2003) Ann N Y Acad Sci 1010:365–373
Alves NL, van Lier RA, Eldering E (2006) Trends Immunol
Aziz MH, Nihal M, Fu VX, Jarrard DF, Ahmad N (2006) Mol Cancer Ther 5:1335–1341
Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA (2006) Nature
Baur JA, Sinclair DA (2006) Nat Rev Drug Discov 5:493–506
Bhat KP, Pezzuto JM (2002) Ann N Y Acad Sci 957:210–229
Cahuzac N, Baum W, Kirkin V, Conchonaud F, Wawrezinieck L, Marguet D, Janssen O, Zornig M, Hueber AO (2006) Blood 107:2384–2391
Cheng WC, Berman SB, Ivanovska I, Jonas EA, Lee SJ, Chen Y, Kaczmarek LK, Pineda F, Hardwick JM (2006) Oncogene 25:4697–4705
Chipuk JE, Bouchier-Hayes L, Green DR (2006) Cell Death Differ 13:1396–1402
Clement MV, Hirpara JL, Chawdhury SH, Pervaiz S (1998) Blood 92:996–1002
Clement MV, Hirpara JL, Pervaiz S (2003) Cell Death Differ 10:1273–1285
Cosgrove MS, Bever K, Avalos JL, Muhammad S, Zhang X, Wolberger C (2006) Biochemistry 45:7511–7521
Cuendet M, Pezzuto JM (2000) Drug Metabol Drug Interact 17:109–157
Dimanche-Boitrel MT, Meurette O, Rebillard A, Lacour S (2005) Drug Resist Updat 8:5–14
Faber AC, Dufort FJ, Blair D, Wagner D, Roberts MF, Chiles TC (2006) Biochem Pharmacol 72:1246–1256
Fulda S, Debatin KM (2005) Eur J Cancer 41:786–798
Galonek HL, Hardwick JM (2006) Nat Cell Biol 8:1317–1319
Gautam SC, Xu YX, Dumaguin M, Janakiraman N, Chapman RA (2000) Bone Marrow Transplant 25:639–645
Gosslau A, Chen M, Ho CT, Chen KY (2005) Br J Cancer 92:513–521
Green DR, Kroemer G (2004) Science 305:626–629
Henkler F, Behrle E, Dennehy KM, Wicovsky A, Peters N, Warnke C, Pfizenmaier K, Wajant H (2005) J Cell Biol 168:1087–1098
Ingram DK, Zhu M, Mamczarz J, Zou S, Lane MA, Roth GS, de Cabo R (2006) Aging Cell 5:97–108
Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM (1997) Science 275:218–220
Kolthur-Seetharam U, Dantzer F, McBurney MW, de Murcia G, Sassone-Corsi P (2006) Cell Cycle 5:873–877
Kopp P (1998) Eur J Endocrinol 138:619–620
Kubo M, Kimurta Y, Shin H, Haneda T, Tani T, Namba K (1981) Shoyakugaku Zasshi 35:58–61
Kundu JK, Chun KS, Kim SO, Surh YJ (2004) Biofactors 21:33–39
Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, Auwerx J (2006) Cell
Langcake P, Pryce RJ (1976) Physiol Plant Pathol 9:77–86
Lee SC, Chan J, Clement MV, Pervaiz S (2006) Proteomics 6:2386–2394
Leibiger IB, Berggren PO (2006) Nat Med 12:34–36; discussion 36
Longo VD, Kennedy BK (2006) Cell 126:257-68
Lu J, Ho CH, Ghai G, Chen KY (2001) Carcinogenesis 22:321–328
Mahyar-Roemer M, Kohler H, Roemer K (2002) BMC Cancer 2:27
Murias M, Handler N, Erker T, Pleban K, Ecker G, Saiko P, Szekeres T, Jager W (2004) Bioorg Med Chem 12:5571–5578
Nonomura S, Kanagawa H, Makimoto A (1963) Yakugaku Zasshi 83:988–990
Ou HC, Chou FP, Sheen HM, Lin TM, Yang CH, Huey-Herng Sheu W (2006) Clin Chim Acta 364:196–204
Pervaiz S (2003) Faseb J 17:1975–1985
Pervaiz S (2004) Drug Resist Updat 7:333–344
Pervaiz S, Cao J, Chao OS, Chin YY, Clement MV (2001) Oncogene 20:6263–6268
Pervaiz S, Ramalingam JK, Hirpara JL, Clement MV (1999) FEBS Lett 459:343–348
Poolman TM, Ng LL, Farmer PB, Manson MM (2005) Free Radic Biol Med 39:118–132
Sexton E, Van Themsche C, Leblanc K, Parent S, Lemoine P, Asselin E (2006) Mol Cancer 5:45
Siemann EH, Creasy LL (1992) An J Eno Vitic 43:49–52
Soleas GJ, Diamandis EP, Goldberg DM (1997) Clin Biochem 30:91–113
Su JL, Lin MT, Hong CC, Chang CC, Shiah SG, Wu CW, Chen ST, Chau YP, Kuo ML (2005) Carcinogenesis 26:1–10
Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK, Lee SS (2001) Mutat Res 480–481:243–268
Tang HY, Shih A, Cao HJ, Davis FB, Davis PJ, Lin HY (2006) Mol Cancer Ther 5:2034–2042
Velthuis JH, Rouschop KM, De Bont HJ, Mulder GJ, Nagelkerke JF (2002) J Biol Chem 277:24631–24637
Wang Y, Wang B, Cheng J, Yang L, Liu ZL, Balan K, Pantazis P, Wyche JH, Han Z (2005) Biochem Pharmacol 69:249–254
Ying W (2006) Front Biosci 11:3129–3148
Zheng J, Ramirez VD (1999) Biochem Biophys Res Commun 261:499–503
Zheng J, Ramirez VD (2000) Br J Pharmacol 130:1115–1123
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Holme, A.L., Pervaiz, S. Resveratrol in cell fate decisions. J Bioenerg Biomembr 39, 59–63 (2007). https://doi.org/10.1007/s10863-006-9053-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10863-006-9053-y